Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Trading 02-12 12:19:21 EST

42.04

-0.92

-2.15%

High43.49	Low41.46	Vol193.30K
Open43.46	D1 Closing42.96	Amplitude4.73%
Mkt Cap2.95B	Tradable Cap2.11B	Total Shares70.07M
T/O8.14M	T/O Rate0.39%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":42.035,"timestamp":1770916759194,"preClose":42.96,"halted":0,"volume":193297,"delay":0,"changeRate":-0.0215316573556798,"floatShares":50198200,"shares":70066174,"eps":-3.99905,"marketStatus":"Trading","change":-0.925,"latestTime":"02-12 12:19:21 EST","open":43.46,"high":43.49,"low":41.46,"amount":8140658.69669,"amplitude":0.047253,"askPrice":42.2,"askSize":27,"bidPrice":41.97,"bidSize":370,"shortable":3,"etf":0,"ttmEps":-3.99905,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":42.96,"preHourTrading":{"tag":"盘前","latestPrice":42.56,"preClose":42.96,"latestTime":"09:23 EST","volume":7040,"amount":303833.61536,"timestamp":1770906214108,"change":-0.4,"changeRate":-0.009311,"amplitude":0.077514},"postHourTrading":{"tag":"盘后","latestPrice":42.5,"preClose":42.96,"latestTime":"19:03 EST","volume":92991,"amount":3995231.99,"timestamp":1770854581113,"change":-0.46,"changeRate":-0.010708,"amplitude":0.023045},"volumeRatio":0.465098,"impliedVol":0.9769,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/VERA/tweets","defaultTab":"tweets","newsList":[{"id":"2609565511","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609565511","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609565511?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:05","pubTimestamp":1770411900,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Feb.  06, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/06/3234072/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4539","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2607021514","title":"Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton","url":"https://stock-news.laohu8.com/highlight/detail?id=2607021514","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607021514?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:05","pubTimestamp":1769807142,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Laurence Matthew Skelton as the beneficial owner, who serves as the company's Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDLbzR4J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BK4588","BK4139","VERA"],"gpt_icon":0},{"id":"2606871662","title":"Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606871662","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606871662?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Jan. 28, 2026  -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial.\"We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"With his track record of building comprehensive commercial organizations and successfully launching multiple therapeutics, Matt's leadership will be critical in our ambition to change what's possible for patients in need.\". \"I am excited to spearhead our launch readiness activities and guide our evolution into a commercial-stage company,\" said Matt Skel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0868494617.USD","LU0942090050.USD","BK4585","LU2347655073.USD","BK4550","LU1244550577.SGD","LU0256863811.USD","LU0912757837.SGD","LU1069347547.HKD","IE00BJJMRX11.SGD","MCD","BK4610","LU1585245621.USD","IE0004445015.USD","LU0417517546.SGD","BK4534","LU2279689827.SGD","IE00B7KXQ091.USD","IE00BJTD4N35.SGD","IE00BJTD4V19.USD","LU1074936037.SGD","LU1035773651.USD","TACI","LU2133065610.SGD","LU0795875086.SGD","LU0726765562.USD","LU0868494708.USD","BK4581","LU1430594728.SGD","LU1732799900.SGD","BK4504","BK4539","LU2347655156.SGD","LU1244550494.USD","LU1718418525.SGD","LU1732800096.USD","VERA","LU1244550221.USD","BK4588","BK4139","IE00BJJMRY28.SGD","BK4209","IE00BFSS8Q28.SGD","BK4566","IE00BFSS7M15.SGD","FSGS"],"gpt_icon":0},{"id":"2606785859","title":"Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2606785859","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606785859?lang=en_us&edition=fundamental","pubTime":"2026-01-27 15:16","pubTimestamp":1769498168,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) is back on investors’ radar after Voya Investment Management’s Voya MidCap Opportunities Fund cited the stock as a top contributor, following successful phase three kidney disease trial results and progress in AI enabled drug discovery.\nSee our latest analysis for Vera Therapeutics.\nThe recent clinical success and AI enabled pipeline work have kept Vera Therapeutics in focus, even as the 1 month share price return of 11.87% decline contrasts with a strong 90 day share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-after-phase-three","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-after-phase-three","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","VERA","BK4585","BK4539","DCF","BK4097","LU2065732104.USD","BK4588","PRGS"],"gpt_icon":0},{"id":"2602303259","title":"Vera Therapeutics Grants Stock Options and RSUs to New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602303259","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602303259?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:05","pubTimestamp":1767981906,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. has granted inducement awards to eighteen new employees under its 2024 Inducement Plan. The awards include non-qualified stock options to purchase 228,750 shares of Class A common stock at an exercise price of $47.07 per share, and restricted stock units  covering 116,000 shares. The stock options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the next 36 months. RSUs will vest over four years, with 25% vesting on each anniversary of February 20, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL44ZdjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","VERA","BK4112","BK4539","LU2095319765.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588"],"gpt_icon":0},{"id":"2601383269","title":"BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383269?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:51","pubTimestamp":1767811889,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y80LY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RTX","HL","W","COMP","FSLR","LMT","CDE","MTB","TXR","ACI","PRAX","CRNX","HUM","IONS","BKR","HAL","SLB","BA","VTYX","APOG","DECK","LBRT","AJG","MTYY","LNG","RZLT","AIR","CL","UNF","LOW","ARWR","VERA","CALM","PENG","NVDA","EXE","NEM","UNP","GE","HSY","GLUE"],"gpt_icon":1},{"id":"2601809779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809779?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:26","pubTimestamp":1767795994,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine FoodsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y80LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOUS","AIR","APOG","DECK","NEM","MSTK","ARWR","AJG","COMP","WNTR","GLUE","IMST","HUM","HSY","MSCI","LMI3.UK","VTYX","VERA","BAC","HL","FSLR","SMI3.UK","07399","MST","PENG","PRAX","09799","CRNX","CDE","CALM","LMT","MSII","MSTY.UK","TXR","CL","RZLT","RTX","SMST","UNP","MSTY","MSST","MTB"],"gpt_icon":1},{"id":"2601808077","title":"BUZZ-Vera soars as FDA accepts priority review for kidney disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808077","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808077?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:51","pubTimestamp":1767790300,"startTime":"0","endTime":"0","summary":"BUZZ-Vera soars as FDA accepts priority review for kidney disease drug** Shares of drug developer Vera Therapeutics VERA.O jump 24% to $57.59 in premarket trading** Co says the U.S. FDA accepted priority review for its experimental drug atacicept to treat IgA nephropathy, a serious kidney disease** IgA nephropathy is an autoimmune condition that can lead to kidney failure in about half of patients, says co** FDA decision expected by July 7 - VERA** Co says late-stage trial showed significant reduction in urine protein levels, a key marker of kidney damage** Drug can be self-administered weekly at home; safety profile similar to placebo, says co** 'Priority review' status is assigned to drugs that offer a significant improvement over other available treatments for a specific disorder or would provide a treatment option where none exists** As of last close, stock down ~8% over the past year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL4N3Y80UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VERA","BK4139","BK4539","BK4588"],"gpt_icon":0},{"id":"2601799808","title":"Vera Therapeutics Shares up 14.4% Premarket After Co Receives U.S. FDA Priority Review for Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601799808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601799808?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:48","pubTimestamp":1767790134,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL4N3Y80UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4539","BK4139","VERA"],"gpt_icon":0},{"id":"2601808435","title":"BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808435?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:38","pubTimestamp":1767789501,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application Jan 7 (Reuters) - Vera Therapeutics Inc VERA.O:VERA THERAPEUTICS ANNOUNCES U.S. FDA GRANTED PRIORITY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5V1RBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","VERA","BK4539"],"gpt_icon":0},{"id":"2601808549","title":"FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808549","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808549?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789024,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. announced that the U.S. Food and Drug Administration  has accepted its Biologics License Application  for atacicept for the treatment of adults with immunoglobulin A nephropathy , granting it Priority Review status. The FDA has set a Prescription Drug User Fee Act  target action date of July 7, 2026. If approved, atacicept would become the first B cell modulator targeting both BAFF and APRIL for IgAN. The BLA submission is supported by positive interim results from the ORIGIN 3 trial, showing significant reductions in proteinuria and a favorable safety profile. Atacicept has also received FDA Breakthrough Therapy Designation for the treatment of IgAN.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeuti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3F7QBw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2095319765.USD","VERA","SG9999014005.SGD","BK4112","BK4539","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2601808555","title":"Vera Therapeutics Inc - Atacicept Receives FDA Breakthrough Therapy Designation for Igan","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808555?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5V1RBY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4539","VERA","BK4139"],"gpt_icon":0},{"id":"2601808530","title":"Vera Therapeutics Inc:  FDA Assigned Pdufa Target Action Date of July 7, 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808530?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5V1RBY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERA","BK4539","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2601580835","title":"Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults With Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601580835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601580835?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5V1RBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4539","VERA","BK4588"],"gpt_icon":0},{"id":"2601558808","title":"Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601558808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601558808?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5V1RBY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERA","BK4585","BK4588","BK4539","BK4139"],"gpt_icon":0},{"id":"2593430249","title":"Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2593430249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593430249?lang=en_us&edition=fundamental","pubTime":"2025-12-23 02:12","pubTimestamp":1766427133,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has been on investors’ radar after upbeat analyst reports flagged two key drivers: rising revenue expectations for kidney drug candidate atacicept and a cash boost from a recent follow on equity raise.\nSee our latest analysis for Vera Therapeutics.\nThe upbeat story around atacicept and the recent equity raise is already showing up in the tape, with a roughly 80 percent 1 month share price return and a near doubling over three months. This builds on a strong 3 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-reassessing-valuation-after-analyst-u","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-reassessing-valuation-after-analyst-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2592915241","title":"Vera Therapeutics Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592915241?lang=en_us&edition=fundamental","pubTime":"2025-12-20 02:02","pubTimestamp":1766167320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2025 13:02 ET (18:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2592196408","title":"Vera Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2592196408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592196408?lang=en_us&edition=fundamental","pubTime":"2025-12-20 00:40","pubTimestamp":1766162400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2025 11:40 ET (16:40 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2592217166","title":"Vera Therapeutics Inc : Bofa Global Research Raises Price Objective to $66.00 From $48.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2592217166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592217166?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:38","pubTimestamp":1766144331,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4585","BK4588","VERA","BK4139"],"gpt_icon":0},{"id":"2592977423","title":"Vera Therapeutics Chief Legal Officer Jason Carter Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977423","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592977423?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:05","pubTimestamp":1766055926,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. announced that Jason Carter will no longer serve as the company's Chief Legal Officer, effective December 24, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLbkTV8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","VERA","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":-0.0753},{"period":"3month","weight":0.5143},{"period":"6month","weight":0.9944},{"period":"1year","weight":0.262},{"period":"ytd","weight":-0.1517}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.025872},{"month":3,"riseRate":0.5,"avgChangeRate":-0.056274},{"month":4,"riseRate":0,"avgChangeRate":-0.100599},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction